Loana B. Valenca
Salvador, BA, Brazil
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Docetaxel Versus Androgen-Receptor Signaling Inhibitors (ARSI) as Second-Line Therapy After Failure of First-Line Alternative ARSI for the Elderly ≥ 75 Years Old With Metastatic Castration-Resistant Prostate Cancer (mCRPC): A SPARTACUSS-Meet-URO 26 Real-World Study.
Journal: Clinical genitourinary cancer
Published: July 30, 2024
Outcomes of First-Line Abiraterone Acetate or Enzalutamide for Older Adults With Metastatic Castration-Resistant Prostate Cancer According to Use of Upfront Docetaxel for Metastatic Castration-Sensitive Prostate Cancer in an International Multicenter Registry: A SPARTACUSS-Meet-URO 26 Study.
Journal: Clinical genitourinary cancer
Published: June 11, 2024
Clinical outcomes of volume of disease on patients receiving enzalutamide versus abiraterone acetate plus prednisone as first-line therapy for metastatic castration-resistant prostate cancer.
Journal: Therapeutic advances in medical oncology
Published: October 25, 2022
Time of metastatic disease presentation and volume of disease are prognostic for metastatic hormone sensitive prostate cancer (mHSPC).
Journal: The Prostate
Published: January 24, 2018
Non-clear cell renal cell carcinoma, part 1: histology.
Journal: Clinical advances in hematology & oncology : H&O
Published: September 10, 2015
Non-clear cell renal cell carcinoma, part 2: therapy.
Journal: Clinical advances in hematology & oncology : H&O
Published: September 10, 2015
Statin Use at the Time of Initiation of Androgen Deprivation Therapy and Time to Progression in Patients With Hormone-Sensitive Prostate Cancer.
Journal: JAMA oncology
Published: July 17, 2015
Sequencing current therapies in the treatment of metastatic prostate cancer.
Journal: Cancer treatment reviews
Published: November 07, 2014
Showing 1-8 of 8
Last Updated: 09/26/2026